1-5 of 5
M. Delforge
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

P. Sonneveld, B. van der Holt, I. G.H. Schmidt-Wolf, U. Bertsch, L. el Jarari, Hans-Jürgen Salwender, S. Zweegman, E. Vellenga, J. Schubert, I. W. Blau, GSK Jie, B. Beverloo, A. Jauch, D. Hose, R. Schaafsma, M. J. Kersten, M. Delforge, O. de Weerdt, R. van der Griend, P. W. Wijermans, Hans Martin, H. van der Velde, Henk M. Lokhorst, H. Goldschmidt
Journal: Blood
Blood (2008) 112 (11): 653.
https://doi.org/10.1182/blood.V112.11.653.653
Published: 2008
Journal Articles

Palifermin Treatment in Patients Receiving High Dose Melphalan or BEAM Prior to Autologous Peripheral Blood Stem-Cell Transplantation.

Anne Sonet, MD, G. Bries, MD, N. Meulemans, MD, A. Van Hoof, MD, E. Steel, MD, M. André, MD, A. Ferrant, MD, N. Straetmans, MD, P. Zachée, MD, V. Robin, MD, H. Demuynck, MD, L. Noens, MD, A. Bosly, MD, M. Delforge, MD, D. Bron, MD
Journal: Blood
Blood (2006) 108 (11): 5241.
https://doi.org/10.1182/blood.V108.11.5241.5241
Published: 2006
Journal Articles

Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups.

T.M. De Witte, MD, A. Hagemeijer, MD, S. Suciu, PhD, A. Belhabri, MD, M. Delforge, MD, C. Aul, MD, M. Aivado, MD, D. Selleslag, MD, H. Schouten, MD, A. Ferrant, MD, H. Biersack, MD, S. Amadori, MD, P. Muus, MD, U. Jehn, MD, F. Beeldens, J. Jansen, PhD, E. Hellstrom-Lindberg, MD, T. Kovacsovics, MD, U. Hess, MD, P. Wijermans, MD, G. Ossenkoppele, MD, A. Gratwohl, MD, J.-P. Marie, MD, R. Willemze, MD
Journal: Blood
Blood (2005) 106 (11): 794.
https://doi.org/10.1182/blood.V106.11.794.794
Published: 2005
Journal Articles

A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups.

M. Oosterveld, MD, S. Suciu, M.Sc, P. Muus, MD, M. Delforge, MD, A. Belhabri, MD, C. Aul, MD, D. Selleslag, MD, A. Ferrant, MD, J.-P. Marie, MD, S. Amadori, MD, U. Jehn, MD, U. Hess, MD, R. Willemze, MD, E. Hellstrom-Lindberg, MD, M. Vignetti, MD, B. Labar, MD, F. Mandelli, MD, T. De Witte, MD
Journal: Blood
Blood (2004) 104 (11): 2020.
https://doi.org/10.1182/blood.V104.11.2020.2020
Published: 2004
Journal Articles

Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes

M Delforge, H Demuynck, P Vandenberghe, G Verhoef, P Zachee, V van Duppen, P Marijnen, H Van den Berghe, MA Boogaerts
Journal: Blood
Blood (1995) 86 (10): 3660–3667.
https://doi.org/10.1182/blood.V86.10.3660.bloodjournal86103660
Published: 1995